CD8A and glioblastoma: Ma et al. constructed an oncolytic HSV-1 to express the human IL15/IL15Rα complex (named OV-IL15C) to investigate its efficacy when administered with EGFR-CAR NK cells in multiple glioblastoma mouse models.327 Compared with monotherapy, the combination therapy increased intracranial infiltration and activation of NK and CD8+ T cells and prolonged the persistence of CAR NK cells, leading to tumor growth inhibition and prolonged survival of tumor-bearing mice.327